STAT3与帕金森病发病机制的研究进展

doi:10.16352/j.issn.1001-6325.2022.12.1935

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (12): 1935-1938.doi: 10.16352/j.issn.1001-6325.2022.12.1935

STAT3与帕金森病发病机制的研究进展

吴长宝¹, 郝延磊^2*

1.济宁医学院临床医学院,山东济宁 272029;
2.济宁医学院附属医院神经内科,山东济宁 272029

收稿日期:2022-06-10 修回日期:2022-09-28 出版日期:2022-12-05 发布日期:2022-11-23
通讯作者: ^* yanleihao301@live.com
基金资助:
国家自然科学基金(81771360); 济宁市重点研发计划项目(2021YXNS101)

Research progress on STAT3 and pathogenesis of Parkinson's disease

WU Chang-bao¹, HAO Yan-lei^2*

1. Medical College of Jining Medical University, Jining 272029;
2. Department of Neurology, Affiliated Hospital of Jining Medical University, Jining 272029, China

Received:2022-06-10 Revised:2022-09-28 Online:2022-12-05 Published:2022-11-23
Contact: ^* yanleihao301@live.com

摘要/Abstract

摘要： 帕金森病(PD)是一种慢性进行性神经退行性疾病。信号传导与转录激活因子3(STAT3)在氧化应激、神经炎性反应、α-突触核蛋白异常聚集、线粒体功能障碍和铁死亡中参与PD的发生和发展,有望成为新的治疗靶点,为PD的治疗提供新的研究思路。

关键词: STAT3转录因子, 帕金森病, 发病机制

Abstract: Parkinson's disease (PD) is a chronic progressive neurodegenerative disease. Signal transducer and activator of transcription 3 (STAT3) is involved in the development and progression of PD, oxidative stress, neuro-inflammatory response, abnormal α-synuclein aggregation, mitochondrial dysfunction and iron death, so they are expected to be a new therapeutic targets and provide new research ideas for the treatment of PD.

Key words: STAT3 transcription factor, Parkinson's disease, pathogenesis

中图分类号:

吴长宝, 郝延磊. STAT3与帕金森病发病机制的研究进展[J]. 基础医学与临床, 2022, 42(12): 1935-1938.

WU Chang-bao, HAO Yan-lei. Research progress on STAT3 and pathogenesis of Parkinson's disease[J]. Basic & Clinical Medicine, 2022, 42(12): 1935-1938.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2022.12.1935

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2022/V42/I12/1935

参考文献

[1]Tran KKN, Wong VHY, Lim JKH, et al. Characterization of retinal function and structure in the MPTP murine model of Parkinson's disease[J].Sci Rep, 2022,12:7610-7620.
[2]Dong J, Cheng XD, Zhang WD, et al. Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation[J].J Med Chem,2021,64:8884-8915.
[3]Qin J, Shen X, Zhang J, et al. Allosteric inhibitors of the STAT3 signaling pathway[J]. Eur J Med Chem, 2020,190:112-122.
[4]Shiah JV, Grandis JR, Johnson DE. Targeting STAT3 with proteolysis targeting chimeras and next-generation antisense oligonucleotides[J].Mol Cancer Ther, 2021,20:219-228.
[5]Liu L, Wang J, Wang H. Hydrogen sulfide alleviates oxidative stress injury and reduces apoptosis induced by MPP⁺ in Parkinson's disease cell model[J].Mol Cell Biochem, 2020,472:231-240.
[6]Xu Z,Yang D,Huang X, et al. Astragaloside Ⅳ protects 6-hydroxydopamine-induced SH-SY5Y cell model of Parkinson's disease via activating the JAK2/STAT3 pathway[J].Front Neurosci,2021,15:631501-631510.
[7]He D,Chen S,Xiao Z, et al. Bisdemethoxycurcumin exerts a cell-protective effect via JAK2/STAT3 signaling in a rotenone-induced Parkinson's disease model in vitro[J].Folia Histochem Cytobiol,2020,58:127-134.
[8]Wang Q, Liu Y. Cryptotanshinone ameliorates MPP⁺-induced oxidative stress and apoptosis of SH-SY5Y neuroblastoma cells: the role of STAT3 in Parkinson's disease[J]. Metab Brain Dis, 2022,37:1477-1485.
[9]Pajares MI, Rojo A, Manda G, et al. Inflammation in Parkinson's disease: mechanisms and therapeutic implications[J].Cells,2020,9:1687-1718.
[10]Wang X, Li X, Zuo X, et al. Photobiomodulation inhibits the activation of neurotoxic microglia and astrocytes by inhibiting Lcn2/JAK2-STAT3 crosstalk after spinal cord injury in male rats[J].J Neuroinflammation, 2021,18:256-275.
[11]Cong L, Lei MY, Liu ZQ, et al. Resveratrol attenuates manganese-induced oxidative stress and neuroinflammation through SIRT1 signaling in mice[J]. Food Chem Toxicol, 2021,153:112283-112295.
[12]Wang X,Liu Z,Wang F.MicroRNA-93 blocks signal transducers and activator of transcription 3 to reduce neuronal damage in Parkinson's dsease[J].Neurochem Res,2021,46:1859-1868.
[13]Hashioka S, McGeer EG, et al. Interferon-γ-induced neurotoxicity of human astrocytes[J]. CNS Neurol Disord Drug Targets,2015,14:251-256.
[14]Choi JY, Yun J, Hwang CJ, et al. (E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl) phenol ameliorates MPTP-induced dopaminergic neurodegeneration by inhibiting the STAT3 pathway[J].Int J Mol Sci,2019,20:2632-2647.
[15]Srinivasan E, Chandrasekhar G, Chandrasekar P, et al. Alpha-synuclein aggregation in Parkinson's disease[J].Front Med,2021:736978.
[16]Li Y, Xia Y, Yin S, et al. Targeting microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 inflammasome axis in Parkinson's dsease[J].Front Immunol, 2021,12:719807-719822.
[17]Zhang J, Zhou DW, Zhang Z, et al.miR-let-7a suppres-ses α-Synuclein-induc-ed microglia inflammation through targeting STAT3 in Parkinson's disease[J].Biochem Biophys Res Commun,2019,519:740-746.
[18]Liu J, Shi M, Hong Z, et al. Identification of ciliary neurotrophic factor receptor alpha as a mediator of neurotoxi-city induced by alpha-synuclein[J]. Proteomics,2010,10:2138-2150.
[19]Iravanpour F, Dargahi L, Rezaei M, et al. Intranasal insulin improves mitochondrial function and attenuates motor deficits in a rat 6-OHDA model of Parkinson's disease[J].CNS Neurosci Ther, 2021,27:308-319.
[20]Zeng L, Li A, Zhang Z, et al. Ropivacaine induces cell cycle arrest in the G0/G1 Phase and apoptosis of PC12 cells via inhibiting mitochondrial STAT3 translocation[J].Inflammation,2021,44:2362-2376.
[21]Qian ZM, Ke Y. Hepcidin and its therapeutic potential in neurodegenerative disorders[J].Med Res Rev, 2020,40:633-653.
[22]Billesbølle CB, Azumaya CM, Kretsch RC, et al. Struc-ture of hepcidin-bound ferroportin reveals iron homeostatic mechanisms[J].Nature, 2020,586:807-811.
[23]Angelova PR, Esteras N, Abramov AY. Mitochondria and lipid peroxidation in the mechanism of neurodegeneration: Finding ways for prevention[J].Med Res Rev, 2021,41:770-784.
[24]Deng H, Liu S, Pan D, et al. Myricetin reduces cytotoxicity by suppressing hepcidin expression in MES23.5 cells[J].Neural Regen Res,2021,16:1105-1110.

STAT3与帕金森病发病机制的研究进展

Research progress on STAT3 and pathogenesis of Parkinson's disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	林柏柏, 钱风华, 钱义明, 赵雷, 孙旗, 褚梦瑶, 沈梦雯. 脓毒症并发毛细血管渗漏综合征的研究进展[J]. 基础医学与临床, 2022, 42(7): 1144-1147.
[2]	赵肖灵, 何润之, 孙玉姣, 张小冲, 杨林芳, 王瑞, 程芳. 活动期白癜风患者血清γ干扰素含量升高[J]. 基础医学与临床, 2022, 42(7): 1067-1070.
[3]	左赋兴, 苑青, 蔡洪庆, 韩睿钦, 万经海. 新型微量注射装置在建立帕金森病模型小鼠中的应用[J]. 基础医学与临床, 2022, 42(7): 1031-1034.
[4]	王行行, 王导新. NETs与急性呼吸窘迫综合征的研究进展[J]. 基础医学与临床, 2021, 41(7): 1047-1051.
[5]	马利芳, 梁建庆, 何建成, 孙雪, 梁鹏. 谷氨酸转运体在帕金森病发病机制中作用的研究进展[J]. 基础医学与临床, 2021, 41(12): 1813-1817.
[6]	邢靖松, 克甜甜, 张琳, 梁东, 张桐, 高尚锋. Spinophilin在神经系统疾病中的研究进展[J]. 基础医学与临床, 2021, 41(10): 1507-1509.
[7]	兰菲, 刘太阳, 杨杰. 肠离子通道在肠易激综合征发病机制中的作用研究进展[J]. 基础医学与临床, 2020, 40(8): 1135-1139.
[8]	宋华琛唐晓楠张海婧王文杰吴练秋. 结肠炎相关结肠癌机制研究进展[J]. 基础医学与临床, 2018, 38(4): 568-572.
[9]	黄体龙杨跃煌张娴文. 间变性淋巴瘤激酶与神经母细胞瘤[J]. 基础医学与临床, 2018, 38(12): 1791-1794.
[10]	李甜甜张江宇李荔. PI3K/Akt在多囊卵巢综合征发病机制中作用的研究进展[J]. 基础医学与临床, 2016, 36(11): 1596-1602.
[11]	翟骁段国礼沈下贤陈晓. α-突触核蛋白在帕金森病中的作用[J]. 基础医学与临床, 2012, 32(12): 1481-1483.
[12]	赵长振. 阿米洛利对PC12细胞的保护作用及其对分子伴侣自噬通路的影响[J]. 基础医学与临床, 2011, 31(10): 1124-1128.
[13]	吴晶晶陈彪. 小胶质细胞通过IL-1加重帕金森病进展[J]. 基础医学与临床, 2010, 30(10): 1100-1104.
[14]	梁彩霞徐云智赵春礼郑德宇段德义 . HLA A表达沉默和酪氨酸羟化酶过表达人成纤维细胞脑内移植治疗帕金森病大鼠模型[J]. 基础医学与临床, 2009, 29(7): 697-703.
[15]	张莉王彦永崔冬生顾平王铭维. LPS致大鼠黑质多巴胺能神经元及血清TNF-α变化的研究[J]. 基础医学与临床, 2008, 28(7): 747-751.